Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Melphalan intravenous - Acrotech Biopharma

Next Previous
X
Search
Drug Profile

Melphalan intravenous - Acrotech Biopharma

Alternative Names: Captisol-Enabled® melphalan; CE melphalan; CE-Melphalan HCl; EVOMELA; LGD-353; sulfobutylether β-cyclodextrin-enabled melphalan

Latest Information Update: 11 Jul 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CyDex Pharmaceuticals
  • Developer Acrotech Biopharma; Boston Medical Center; CASI Pharmaceuticals
  • Class Amino acids; Antineoplastics; Aromatic amino acids; Myeloablative agonists; Nitrogen mustard compounds; Small molecules
  • Mechanism of Action Alkylating agents; DNA damage stimulants; DNA synthesis inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase II Amyloidosis

Most Recent Events

  • 06 Jul 2022 Spectrum Pharmaceuticals and Boston Medical Center terminates a phase II trial in Amyloidosis in USA (IV) due to slow accrual during COVID-2019 pandemic (NCT02994784)
  • 04 Mar 2022 CASI Pharmaceuticals announces the renewal of distribution agreement with China Resources Guokang Pharmaceuticals for the distribution of melphalan in China
  • 12 Aug 2019 Launched for Multiple myeloma in China (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top